Tucidinostat | Chidamide | HDAC Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / 组蛋白去乙酰化酶 / Tucidinostat

西达本胺 /Tucidinostat {[allProObj[0].p_purity_real_show]}

货号：A617381 同义名： Chidamide;HBI-8000

Tucidinostat is an inhibitor of HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor with IC50s of 95, 160, 67 and 78 nM, espectively.

Tucidinostat 化学结构
CAS号：1616493-44-7

Tucidinostat 3D分子结构
CAS号：1616493-44-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Tucidinostat 纯度/质量文件产品仅供科研

货号：A617381 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-A, IC50: 16 nM HD1-B, IC50: 7.5 nM	+++ HD2, IC50: 10 nM														{[allProObj[0].p_purity_real_show]}
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															{[allProObj[0].p_purity_real_show]}
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													{[allProObj[0].p_purity_real_show]}
Scriptaid			✔													{[allProObj[0].p_purity_real_show]}
Valproic acid sodium			✔												Autophagy	{[allProObj[0].p_purity_real_show]}
AR-42			+++ HDAC, IC50: 30 nM													{[allProObj[0].p_purity_real_show]}
Dacinostat			+++ HDAC, IC50: 32 nM													{[allProObj[0].p_purity_real_show]}
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	{[allProObj[0].p_purity_real_show]}
M344			++ HDAC, IC50: 100 nM													{[allProObj[0].p_purity_real_show]}
Splitomicin			+ Sir2p, IC50: 60 μM													{[allProObj[0].p_purity_real_show]}
Panobinostat			++++ HDAC (Reh cells), IC50: 20 nM HDAC (MOLT-4 cells), IC50: 5 nM													{[allProObj[0].p_purity_real_show]}
Sodium 4-Phenylbutyrate			✔													{[allProObj[0].p_purity_real_show]}
Vorinostat			+++ HDAC, IC50: ~10 nM													{[allProObj[0].p_purity_real_show]}
Curcumin			✔												Nrf2,NF-κB	{[allProObj[0].p_purity_real_show]}
Belinostat			+++ HDAC, IC50: 27 nM													{[allProObj[0].p_purity_real_show]}
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								{[allProObj[0].p_purity_real_show]}
Valproic acid				+ HDAC1, IC50: 0.4 mM												{[allProObj[0].p_purity_real_show]}
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								{[allProObj[0].p_purity_real_show]}
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								{[allProObj[0].p_purity_real_show]}
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					{[allProObj[0].p_purity_real_show]}
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									{[allProObj[0].p_purity_real_show]}
Parthenolide				✔											NF-κB,p53	{[allProObj[0].p_purity_real_show]}
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								{[allProObj[0].p_purity_real_show]}
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								{[allProObj[0].p_purity_real_show]}
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					{[allProObj[0].p_purity_real_show]}
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					{[allProObj[0].p_purity_real_show]}
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								{[allProObj[0].p_purity_real_show]}
Santacruzamate A							++++ HDAC2, IC50: 119 pM									{[allProObj[0].p_purity_real_show]}
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								{[allProObj[0].p_purity_real_show]}
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						{[allProObj[0].p_purity_real_show]}
Tasquinimod									✔							{[allProObj[0].p_purity_real_show]}
CAY10603											++++ HDAC6, IC50: 2 pM					{[allProObj[0].p_purity_real_show]}
Tubastatin A											+++ HDAC6, IC50: 15 nM					{[allProObj[0].p_purity_real_show]}
Tubacin											++++ HDAC6, IC50: 4 nM					{[allProObj[0].p_purity_real_show]}
ACY-738											++++ HDAC6, IC50: 1.7 nM					{[allProObj[0].p_purity_real_show]}
Nexturastat A											++++ HDAC6, IC50: 5 nM					{[allProObj[0].p_purity_real_show]}
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			{[allProObj[0].p_purity_real_show]}
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			{[allProObj[0].p_purity_real_show]}
PCI-34051													+++ HDAC8, IC50: 10 nM			{[allProObj[0].p_purity_real_show]}
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			{[allProObj[0].p_purity_real_show]}
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			{[allProObj[0].p_purity_real_show]}
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			{[allProObj[0].p_purity_real_show]}
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			{[allProObj[0].p_purity_real_show]}
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			{[allProObj[0].p_purity_real_show]}
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			{[allProObj[0].p_purity_real_show]}
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		{[allProObj[0].p_purity_real_show]}
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		{[allProObj[0].p_purity_real_show]}
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		{[allProObj[0].p_purity_real_show]}
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Tucidinostat 生物活性

靶点	HDAC10 HDAC10, IC50:78 nM HDAC3 HDAC3, IC50:67 nM HDAC2 HDAC2, IC50:160 nM HDAC1 HDAC1, IC50:95 nM
描述	Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.

Tucidinostat 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02718066	Melanoma Rena... 展开 >>l Cell Carcinoma Non-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	January 2020	United States, Arizona ... 展开 >> [Site 02] Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Thai Ho United States, California [Site 11] University of California, San Diego Medical Center Recruiting La Jolla, California, United States, 92037 Contact: Lyudmila Bazhenova United States, Florida [Site 01] Hematology - Oncology Associates of the Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 34952 Contact: Heather Yeckes-Rodin [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. Recruiting Tampa, Florida, United States, 33612 Contact: Nikhil Khushalani United States, Maryland [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute Recruiting Frederick, Maryland, United States, 21702 Contact: Elhamy Eskander United States, Texas [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics Recruiting Houston, Texas, United States, 77030 Contact: Siqing Fu 收起 <<
NCT03574402	Carcinoma, Non-Small-Cell Lung	Phase 2	Not yet recruiting	December 30, 2024	-
NCT02697552	Non-Hodgkin's Lymphoma	Phase 1	Completed	-	Japan ... 展开 >> Nagoya City University Hospital Aichi, Japan Fukuoka University Hospital Fukuoka, Japan NHO Kyushu Cancer Center Fukuoka, Japan Kagoshima University Medical and Dental Hospital Kagoshima, Japan Tokai University Hospital Kanagawa, Japan NHO Kumamoto Medical Center Kumamoto, Japan NHO Nagasaki Medical Center Nagasaki, Japan National Cancer Center Hospital Tokyo, Japan 收起 <<

Tucidinostat 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.81mL

2.56mL

1.28mL

25.61mL

5.12mL

2.56mL

Tucidinostat 技术信息

CAS号	1616493-44-7
分子式	C₂₂H₁₉FN₄O₂
分子量	390.41

别名	Chidamide;HBI-8000;CS 055
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(128.07 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

PO 5%DMSO + 30%PEG400 + 5%tween80 + 60%Water 3 mg/mL clear

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02718066	Melanoma Rena... 展开 >>l Cell Carcinoma Non-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	January 2020	United States, Arizona ... 展开 >> [Site 02] Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Thai Ho United States, California [Site 11] University of California, San Diego Medical Center Recruiting La Jolla, California, United States, 92037 Contact: Lyudmila Bazhenova United States, Florida [Site 01] Hematology - Oncology Associates of the Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 34952 Contact: Heather Yeckes-Rodin [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. Recruiting Tampa, Florida, United States, 33612 Contact: Nikhil Khushalani United States, Maryland [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute Recruiting Frederick, Maryland, United States, 21702 Contact: Elhamy Eskander United States, Texas [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics Recruiting Houston, Texas, United States, 77030 Contact: Siqing Fu 收起 <<
NCT03574402	Carcinoma, Non-Small-Cell Lung	Phase 2	Not yet recruiting	December 30, 2024	-
NCT02697552	Non-Hodgkin's Lymphoma	Phase 1	Completed	-	Japan ... 展开 >> Nagoya City University Hospital Aichi, Japan Fukuoka University Hospital Fukuoka, Japan NHO Kyushu Cancer Center Fukuoka, Japan Kagoshima University Medical and Dental Hospital Kagoshima, Japan Tokai University Hospital Kanagawa, Japan NHO Kumamoto Medical Center Kumamoto, Japan NHO Nagasaki Medical Center Nagasaki, Japan National Cancer Center Hospital Tokyo, Japan 收起 <<
NCT03605056	Multiple Myeloma	Phase 2	Not yet recruiting	July 31, 2022	China, Shanghai ... 展开 >> 180 Fenglin Road Active, not recruiting Shanghai, Shanghai, China, 200032 收起 <<
NCT03617432	Experimental Tumor	Phase 2	Recruiting	September 30, 2022	China ... 展开 >> Beijing Cancer Hospital Recruiting Beijing, China, 100142 Contact: Jun Zhu, MD +86-10-88196596 zj@bjcancer.org Contact: Weiping Liu, MD +86-10-88196109 dreaming2217@126.com Principal Investigator: Jun Zhu, MD 收起 <<
NCT03602131	Hodgkin Lymphoma ... 展开 >> Non-hodgkin Lymphoma 收起 <<	Phase 2	Not yet recruiting	March 30, 2021	-
NCT03321890	Peripheral T-cell Lymphoma	Phase 2	Recruiting	December 31, 2020	China, Guangdong ... 展开 >> Department of Medical Oncology,Sun Yat-Sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Zhiming Li, DM +86-13719189172 Lizhm@sysucc.org.cn Contact: Yu Wang, DM 86-20-87343765 Wangyu@sysucc.org.cn 收起 <<
NCT03151876	Lymphoma	Phase 2	Recruiting	December 2021	China, Beijing ... 展开 >> Beijing cancer hospital Not yet recruiting Beijing, Beijing, China, 100142 Contact: Yan Xie, MD Peking university third hospital Not yet recruiting Beijing, Beijing, China, 100191 Contact: Xiaoyan Ke, MD China, Chongqing The first affiliated hospital of Chongqing medical university Not yet recruiting Chongqing, Chongqing, China, 400016 Contact: Lin Liu, MD Southwest Hospital Recruiting Chongqing, Chongqing, China, 400038 Contact: Dabing Qin, MD China, Gansu General Hospital of Lanzhou military command Not yet recruiting Lanzhou, Gansu, China, 730070 Contact: Hai Bai, MD China, Henan Henan cancer hospital Not yet recruiting Zhengzhou, Henan, China, 450008 Contact: Jian Zhou, MD The first affiliated hospital of Zhengzhou university Not yet recruiting Zhengzhou, Henan, China, 450052 Contact: Xinhua Wang, MD China, Hubei Tongji Hospital Not yet recruiting Wuhan, Hubei, China, 430030 Contact: Yang Cao, MD China, Jiangsu Jiangsu province hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Wei Xu, MD China, Shanghai Rui jin hospital Shanghai jiao tong University Not yet recruiting Shanghai, Shanghai, China, 200025 Contact: Jiong Hu, MD Tong Ren Hospital Not yet recruiting Shanghai, Shanghai, China Contact: Ligen L i u, MD China, Shanxi Shan Xi Da Yi Hospital Not yet recruiting Taiyuan, Shanxi, China, 030032 Contact: Rong Gong, MD Tangdu Hospital Not yet recruiting Xi'an, Shanxi, China, 710038 Contact: Qiang Liu, MD China, Sichuan West China Hospital of Sichuan University Recruiting Chengdu, Sichuan, China, 610044 Contact: Jie Ji, MD 86-28-85422370 jieji@scu.edu.cn Affiliated Hospital of Southwest Medical University Recruiting Nanchong, Sichuan, China, 646000 Contact: Xiaoming Li, MD China, Tianjing Blood diseases hospital, Chinese academy of medica Not yet recruiting Tianjin, Tianjing, China, 300020 Contact: Lvgui Qiu, MD China, Xinjiang The first affiliated hospital of Xinjiang medical Universtiy Not yet recruiting Ürümqi, Xinjiang, China, 830054 Contact: Ming Jiang, MD China, Yunnan Kunming General Hospital of Chengdu Military Area Not yet recruiting Kunming, Yunnan, China, 650032 Contact: Sanbin Wang, MD 收起 <<
NCT03564704	Leukemia Leuk... 展开 >>emia, Acute Adult Lymphoblastic Lymphoma Leukemia, Lymphoblastic Leukemia, T Cell Adult Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Lymphoblastic Leukemia 收起 <<	Phase 2 Phase 3	Recruiting	May 30, 2021	China, Guangdong ... 展开 >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou +862062787349 zhs1@i.smu.edu.cn 收起 <<
NCT03629873	Lymphoma, Large B-Cell, Diffus... 展开 >>e Mantle Cell Lymphoma Peripheral T Cell Lymphoma Double-hit Lymphoma 收起 <<	Phase 2	Recruiting	August 1, 2020	China, Jiangsu ... 展开 >> Hematological Department, People's Hospital of Jiangsu Province Recruiting Nanjing, Jiangsu, China, 210029 Contact: Wei Xu, Ph.D. +86-2568302182 xuwei10000@hotmail.com 收起 <<
NCT02879526	Relapse/Refratory Peripheral T... 展开 >> Cell Lymphoma 收起 <<	Phase 2	Recruiting	August 2019	China, Jiangsu ... 展开 >> HuaiAn First People's Hospital Recruiting HuaiAn, Jiangsu, China, 223300 Contact: Liang Yu, M.D., Ph.D. WuXi People's Hospital Recruiting WuXi, Jiangsu, China, 214023 Contact: Yun Zhuang, M.D. Contact: YunFeng Shen, M.D., Ph.D 收起 <<
NCT03023358	Peripheral T Cell Lymphoma	Phase 3	Not yet recruiting	March 2019	China, Guangdong ... 展开 >> Ru Feng Not yet recruiting Guangzhou, Guangdong, China, 510515 Contact: Ru Feng, M.D. +86 13725119762 ruth1626@hotmail.com Contact: Qi Wei, M.D. +86 13427564102 sinbad37@126.com Principal Investigator: Ru Feng, M.D. 收起 <<
NCT03553238	Leukemia, Acute ... 展开 >> Leukemia, T Cell Leukemia, Lymphoblastic 收起 <<	Phase 2 Phase 3	Recruiting	August 30, 2020	China, Guangdong ... 展开 >> Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, MD, PhD +862062787349 zhs1@i.smu.edu.cn 收起 <<
NCT03453255	Chemotherapy	Phase 1 Phase 2	Recruiting	December 31, 2020	China ... 展开 >> Chinese PLA General Hospital Recruiting Beijing, China, 100853 Contact: Li Yu, M.D. Ph.D. 86-010-55499003 chunhuiliyu@yahoo.com Principal Investigator: Li Yu, M.D. Ph.D. 收起 <<
NCT02753647	Diffuse Large B-cell Lymphoma	Phase 2	Recruiting	April 2019	China, Shanghai ... 展开 >> Shanghai Ruijin Hospital Recruiting Shanghai, Shanghai, China, 200023 Contact: Weili Zhao, MD,PhD 64370045 ext 610707 zhao.weili@yahoo.com Contact: Pengpeng Xu, MD 64370045 ext 610707 xpproc@msn.com 收起 <<
NCT02809573	Peripheral T-cell Lymphoma	Phase 1	Recruiting	December 2019	China, Beijing ... 展开 >> Cancer Hospital, Chinese Academy of Medical Sciences Recruiting Beijing, Beijing, China, 100000 Contact: Yuankai Shi, MD +86-10-8778-8293 syuankai@cicams.ac.cn 收起 <<
NCT03564470	Leukemia Leuk... 展开 >>emia, Acute Leukemia, Lymphoblastic Leukemia, B-cell 收起 <<	Phase 2 Phase 3	Recruiting	August 30, 2020	China, Guangdong ... 展开 >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, PhD, MD 86-20-62787349 zhs1@i.smu.edu.cn 收起 <<
NCT02733380	Diffuse Large B-cell Lymphoma	Phase 2	Recruiting	May 2020	China, Henan ... 展开 >> Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Recruiting ZhengZhou, Henan, China, 450008 Contact: Yanyan Liu, M.D. +8613838176375 yyliu@zzu.edu.cn Contact: Jiuyang Zhang, Master +8615003810435 zhangjiuyang9103@163.com Principal Investigator: Yanyan Liu, M.D. 收起 <<
NCT01836679	Non-small-cell Lung Cancer	Phase 2	Completed	-	China, Beijing ... 展开 >> Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China, 101149 China, Hebei Hebei Provincial Tumor Hospital Shijiazhuang, Hebei, China, 050011 China, Jiangsu Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210009 China, Liaoning The first Hospital of China Medical University Shenyang, Liaoning, China, 110001 China, Shanghai Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University Shanghai, Shanghai, China, 200030 China, Sichuan The Second People's Hospital of Sichuan Chengdu, Sichuan, China, 82816 China, Tianjin Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China, 300060 收起 <<
NCT02987244	T Cell Non-Hodgkin's Lymphoma	Phase 1 Phase 2	Recruiting	March 2023	China, Beijing ... 展开 >> Peking Union medical college hospital Recruiting Beijing, Beijing, China, 100730 Contact: Wei Zhang China, Tianjin Tianjin medical universty cancer institute & hospital Recruiting Tianjin, Tianjin, China, 300060 收起 <<
NCT02886559	AML Relapse	Phase 1 Phase 2	Recruiting	June 2019	China ... 展开 >> China PLA General Hospital Recruiting Beijing, China, 100039 Contact: Li Yu, M.D Ph.D 010-66937644 chunhuiliyu@yahoo.com Principal Investigator: Li-Xin Yu 收起 <<
NCT03630731	Natural Killer/T-Cell Lymphoma... 展开 >>, Nasal and Nasal-Type 收起 <<	Phase 2	Recruiting	March 2020	China, Beijing ... 展开 >> Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Mei Dong (86)13811929322 dongmei030224@163.com 收起 <<
NCT03598959	Extranodal NK/T-cell Lymphoma	Phase 2	Not yet recruiting	December 31, 2021	China, Sichuan ... 展开 >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 收起 <<
NCT03336632	Leukemia, Acute ... 展开 >> MDS 收起 <<	Phase 2	Not yet recruiting	March 30, 2021	China, Sichuan ... 展开 >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 West China Hospital of Sichuan University Not yet recruiting Chengdu, Sichuan, China, 610044 Contact: Jie Ji, MD 86-28-85422370 jieji@scu.edu.cn 收起 <<
NCT03273452	Angioimmunoblastic T-cell Lymp... 展开 >>homa 收起 <<	Phase 2	Recruiting	May 2019	China, Shandong ... 展开 >> The Affiliated Hospital of Qingdao University Recruiting Qingdao, Shandong, China, 266000 Contact: Hongwei Xue, MD. PhD (+86)13475875599 Xuehongwei1867@163.com 收起 <<
NCT03611231	Experimental Tumor	Phase 2	Not yet recruiting	December 30, 2022	China, Beijing ... 展开 >> Beijing Not yet recruiting Beijing, Beijing, China, 100000 Contact: Yuqin Song, Dr. 0086 ‭13683398726 songyuqin622@163.com 收起 <<
NCT02753543	Peripheral T Cell Lymphoma	Phase 2	Recruiting	November 2019	China, Shanghai ... 展开 >> Ruijin Hospital Recruiting Shanghai, Shanghai, China, 200023 Contact: Weili Zhao, MD, PhD 64370045 ext 610707 zhao.weili@yahoo.com Contact: Pengpeng Xu, MD 64370045 ext 610707 xpproc@msn.com 收起 <<
NCT03031262	AML	Phase 1 Phase 2	Recruiting	December 2022	China, Tianjin ... 展开 >> Institute of Hematology & Blood Diseases Hospital Recruiting Tianjin, Tianjin, China Contact: lijun Liu 86-22-23909237 bloodgcp@126.com 收起 <<
NCT03245905	Relapsed or Refractory B-cell ... 展开 >>Non-Hodgkin's Lymphoma (NHL) 收起 <<	Phase 2	Not yet recruiting	September 30, 2019	China, Guangdong ... 展开 >> Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, 510060 收起 <<
NCT03201471	Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	February 5, 2020	China, Zhejiang ... 展开 >> The first affiliated hospital of Zhejiang University Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Wenbin Qian, MD. PhD. (+86)13605801032 收起 <<
NCT02902185	Chronic HIV Infections	Phase 2 Phase 3	Active, not recruiting	December 2018	China, Guangxi ... 展开 >> The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China China, Shaanxi Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University Xi'an, Shaanxi, China, 710038 China, Zhejiang Zhejiang University Hangzhou, Zhejiang, China 收起 <<
NCT03494634	Experimental Tumor	Phase 2	Not yet recruiting	September 30, 2020	China, Guangdong ... 展开 >> Cancer Center of Sun Yat-Sen University (CCSU) Guangzhou, Guangdong, China 收起 <<
NCT02482753	Breast Cancer	Phase 3	Active, not recruiting	March 2019	China, Beijing ... 展开 >> The 307th Hospital of Chinese people's Liberation Army Beijing, Beijing, China, 100021 收起 <<
NCT02883374	Adenocystic Carcinoma	Phase 2	Recruiting	June 2020	China, Beijing ... 展开 >> Cancer Hospital, Chinese Academy of Medical Science Recruiting Beijing, Beijing, China, 100021 Contact: Mei Dong, Doctor 13811929322 dongmei030224@163.com Principal Investigator: Mei Dong, Doctor 收起 <<
NCT03268889	Peripheral T Cell Lymphoma	Not Applicable	Recruiting	September 15, 2020	China, Jiangsu ... 展开 >> the First Affiliated Hospital of Soochow University Recruiting Suzhou, Jiangsu, China, 215006 Contact: Zhengming Jin, MD, PhD (+86)512-67781856 收起 <<
NCT03410004	Experimental	Phase 2	Not yet recruiting	September 30, 2020	-
NCT02856997	Peripheral T Cell Lymphoma	Phase 2	Not yet recruiting	-	-
NCT02815007	Advanced EGFR-TKI-resistant No... 展开 >>n-Small Cell Lung Cancer 收起 <<	Phase 2	Unknown	June 2018	-
NCT03105596	B-cell Non-Hodgkin's Lymphoma	Phase 2	Not yet recruiting	September 30, 2019	-
NCT03639168	Adenoid Cystic Carcinomas ... 展开 >> Chidamide Cisplatin 收起 <<	Phase 2	Recruiting	June 1, 2020	China, Shanghai ... 展开 >> Kai Xue Recruiting Shanghai, Shanghai, China, 200032 Contact: Kai Xue, MD 13818659448 xuekaishanghai@126.com 收起 <<
NCT02878278	Lymphoma, Extranodal NK-T-Cell... 展开 >> EBV 收起 <<	Phase 2	Not yet recruiting	September 2019	-
NCT03373019	Chidamide Lym... 展开 >>phoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasm by Histology Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Cyclophosphamide Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor 收起 <<	Phase 2	Recruiting	March 1, 2021	China, Shanghai ... 展开 >> Kai Xue Recruiting Shanghai, Shanghai, China, 200032 Contact: Kai Xue, MD 13818659448 xuekaishanghai@126.com China Kai Xue Recruiting Shanghai, China Contact: Kai Xue, MD 13818659448 xuekaishanghai@126.com Contact: Junning Cao, MD 13818659448 收起 <<
NCT02944812	Peripheral T Cell Lymphoma	Phase 2	Recruiting	January 2019	China, Guangdong ... 展开 >> Guangdong general hospital Recruiting Guangzhou, Guangdong, China, 510080 Contact: Wenyu Li, MD PhD +86 20 81884713-80412 收起 <<
NCT02513901	Chronic HIV Infections	Phase 1 Phase 2	Completed	-	China, Shaanxi ... 展开 >> Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University Xi'an, Shaanxi, China, 710038 收起 <<

西达本胺 /Tucidinostat {[allProObj[0].p_purity_real_show]}

Tucidinostat 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Tucidinostat 质控信息

Tucidinostat 生物活性

Tucidinostat 临床研究

Tucidinostat 实验方案

Tucidinostat 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

HDAC10	HDAC10, IC50:78 nM
HDAC3	HDAC3, IC50:67 nM
HDAC2	HDAC2, IC50:160 nM
HDAC1	HDAC1, IC50:95 nM

西达本胺 /Tucidinostat {[allProObj[0].p_purity_real_show]}

Tucidinostat 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Tucidinostat 质控信息

Tucidinostat 生物活性

Tucidinostat 临床研究

Tucidinostat 实验方案

Tucidinostat 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Tucidinostat 纯度/质量文件产品仅供科研